Posted: APR 28, 2008

CSMG Technologies Subsidiary Live Tissue Connect Technology and Product Performance Clinical Papers Presented at Central European Congress of Surgery

Corpus Christi, TX, April 28, 2008 -- CSMG Technologies, Inc., (OTCBB: CTGI - News), a technology management company, announced its Live Tissue Connect, Inc. (LTC) subsidiary's technology was presented at the Central European Congress of Surgery in Prague, Czech, April 23rd to 26th, 2008.

Dr. Robert Tucker M.D. PhD, of the University of Iowa, presented three clinical papers peer reviewed at the surgical Congress. Dr. Tucker described his results with Live Tissue Connect's technology and product performance at the Central European Congress of Surgery (CECS). Additionally, LTC had a booth at the exhibition which allowed the LTC team the opportunity to discuss the technology and product performance with leading physicians and European distributors.

The focus of this Congress was on the developing fields of surgery, evidence-based medicine and new technologies. Many international experts attended to share their knowledge and experience in surgery, oncology and radiology at this Congress.

Donald S. Robbins, President and CEO of CSMG Technologies, said, "This is an important milestone for LTC to have Dr. Tucker present his papers at CECS. This was our first opportunity to publicly unveil the RF sealing results that are obtainable with LTC's products, and to compare such to leading RF sealing medical device companies that already have a market presence. Surgeons and distributors attending the Congress showed considerable interest in LTC's technology."

To view LTC Clinical Papers Presented & LTC booth photos at CECS

go to: www.csmgtechinternational.com/presentation.html

CSMG Technologies owns the technology and exclusive world rights to the live tissue bonding device through Live Tissue Connect, Inc., a subsidiary corporation formed for the development and exploitation of the platform technology. European CE Mark has been received on the electrosurgical generator and United States FDA 510(K) clearance documentation has been filed for the duct and vessel sealing product. The duct and vessel sealing electrosurgical generator and associated hand instruments are currently being produced in production quantities.

Surgeons at 27 Ukrainian hospitals and clinics are using the tissue welding/bonding technology in clinical trials. They have completed more than 10,000 human surgeries including more than 80 types of open and laparoscopic surgical procedures, establishing that the technology is universal in its ability to repair soft biological tissue.

U.S., Australian, Canadian, Ukraine and European Union patents have been issued, and additional U.S. and foreign patents are pending. LTC currently owns a total of 31 patents issued or pending.

The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine, Kiev, Ukraine, headed by Professor B.E. Paton.

About CSMG Technologies, Inc.

CSMG Technologies is a technology management company that finances, owns, develops, licenses and markets innovative advanced technologies and business opportunities created in the Ukraine through a network of scientific institutes and private organizations. CSMG is focused on two primary subsidiaries, Live Tissue Connect, Inc. and landfill gas processing.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.csmgtechinternational.com.

Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to: www.csmgtechinternational.com/contact_information.html and fill-in information.

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

CONTACT:

ROI Group Associates, Inc.
Michael Dodge, 212-495-0744
mdodge@roiny.com
or
CSMG Technologies, Inc.
Donald S. Robbins, 361-887-754
President and CEO
or
K. Bruce Jones, 770-955-0409